Company intelligence / Profile preview

Recombio

Ownership: Private
Development stage: Other

Overview

Recombio S.L., headquartered in Madrid, Spain, is an active biotechnology company specializing in immunotherapies—particularly vaccines based on anti-idiotype monoclonal antibodies—for oncology indications such as non-small cell lung cancer. Its lead asset racotumomab ("Vaxira") has received conditional approval and commercialization status for NSCLC treatment in Argentina and Cuba. The company collaborates with Ariana Pharma to leverage AI-driven biomarker discovery to optimize patient selection strategies for its therapies.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyCancer vaccineImmunotherapy
Industry: Biotech

Drug pipeline

1 asset

racotumomab

Partnerships

Ariana Pharma

Beyond the preview

Go deeper on Recombio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recombio.